Immutep Management

Management criteria checks 3/4

Immutep's CEO is Marc Voigt, appointed in Nov 2012, has a tenure of 10.33 years. total yearly compensation is A$1.06M, comprised of 44.8% salary and 55.2% bonuses, including company stock and options. directly owns 0.78% of the company’s shares, worth $2.15M. The average tenure of the management team and the board of directors is 6.9 years and 2.5 years respectively.

Key information

Marc Voigt

Chief executive officer

AU$1.1m

Total compensation

CEO salary percentage44.8%
CEO tenure12yrs
CEO ownership0.8%
Management average tenure6.9yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Marc Voigt's remuneration changed compared to Immutep's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$1mAU$477k

-AU$43m

Mar 31 2024n/an/a

-AU$42m

Dec 31 2023n/an/a

-AU$41m

Sep 30 2023n/an/a

-AU$40m

Jun 30 2023AU$1mAU$440k

-AU$40m

Mar 31 2023n/an/a

-AU$38m

Dec 31 2022n/an/a

-AU$37m

Sep 30 2022n/an/a

-AU$34m

Jun 30 2022AU$943kAU$428k

-AU$32m

Mar 31 2022n/an/a

-AU$29m

Dec 31 2021n/an/a

-AU$26m

Sep 30 2021n/an/a

-AU$28m

Jun 30 2021AU$995kAU$409k

-AU$30m

Mar 31 2021n/an/a

-AU$29m

Dec 31 2020n/an/a

-AU$27m

Sep 30 2020n/an/a

-AU$20m

Jun 30 2020AU$926kAU$411k

-AU$13m

Mar 31 2020n/an/a

-AU$15m

Dec 31 2019n/an/a

-AU$16m

Sep 30 2019n/an/a

-AU$17m

Jun 30 2019AU$837kAU$399k

-AU$18m

Mar 31 2019n/an/a

-AU$18m

Dec 31 2018n/an/a

-AU$17m

Sep 30 2018n/an/a

-AU$15m

Jun 30 2018AU$1mAU$401k

-AU$13m

Compensation vs Market: Marc's total compensation ($USD699.70K) is below average for companies of similar size in the US market ($USD1.47M).

Compensation vs Earnings: Marc's compensation has been consistent with company performance over the past year.


CEO

Marc Voigt (51 yo)

12yrs

Tenure

AU$1,064,669

Compensation

Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...


Leadership Team

NamePositionTenureCompensationOwnership
Marc Voigt
CEO, MD12yrsAU$1.06m0.78%
$ 2.1m
Deanne Miller
COO, General Counsel & Joint Company Secretary12.1yrsAU$565.23k0.18%
$ 508.3k
Frederic Triebel
Chief Scientific Officer & Executive Director9.9yrsAU$864.44k0.61%
$ 1.7m
Florian Vogl
Chief Medical Officer1.5yrsAU$955.82kno data
Christian Mueller
Senior Vice President of Regulatory & Strategy1.1yrsno datano data
Indira Naidu
Joint Company Secretary3.8yrsno datano data

6.9yrs

Average Tenure

51yo

Average Age

Experienced Management: PRRU.F's management team is seasoned and experienced (6.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Marc Voigt
CEO, MD10.3yrsAU$1.06m0.78%
$ 2.1m
Frederic Triebel
Chief Scientific Officer & Executive Director2.2yrsAU$864.44k0.61%
$ 1.7m
Russell Howard
Independent Non-Executive Chairman11.5yrsAU$163.52k0.077%
$ 212.2k
Pete Meyers
Independent Non-Executive Deputy Chairman10.8yrsAU$138.71k0.25%
$ 698.2k
Martine Piccart
Chairman of Clinical Advisory Board7.4yrsno datano data
Scott Antonia
Member of Clinical Advisory Board2.5yrsno datano data
Leisha Emens
Member of Clinical Advisory Board2.5yrsno datano data
Elisabeth Boyce
Non-Executive Director1.6yrsAU$144.76kno data
Salah-Eddin Al-Batran
Member of Clinical Advisory Board7.4yrsno datano data
Martin Forster
Member of Clinical Advisory Board2.5yrsno datano data
Hans Wildiers
Member of Clinical Advisory Board2.5yrsno datano data

2.5yrs

Average Tenure

61.5yo

Average Age

Experienced Board: PRRU.F's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.